» Articles » PMID: 25853369

Short-term Results of a Magnetic Resonance Imaging-Based Swedish Screening Program for Individuals at Risk for Pancreatic Cancer

Overview
Journal JAMA Surg
Specialty General Surgery
Date 2015 Apr 9
PMID 25853369
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Importance: Pancreatic cancer is the fourth leading cause of cancer-related death in Western countries. In approximately 10% of all patients with pancreatic cancer, it is possible to define a positive family history for pancreatic cancer or for one of the other related genetic syndromes. A screening program for individuals at risk is recommended; however, surveillance modalities have not been defined yet.

Objective: To analyze the short-term results of a prospective clinical surveillance program for individuals at risk for pancreatic cancer using a noninvasive magnetic resonance imaging (MRI)-based screening protocol.

Design, Setting And Participants: A prospective observational study of all patients with a genetic risk for developing pancreatic cancer who were referred to Karolinska University Hospital between January 1, 2010, and January 31, 2013, using an MRI-based surveillance program. All patients were investigated for the most common genetic mutations associated with pancreatic cancer.

Exposure: A noninvasive MRI-based screening protocol.

Main Outcomes And Measures: The ability of MRI to identify potential precancerous or early cancers in individuals at risk for pancreatic cancer.

Results: Forty patients (24 women and 16 men) were enrolled. The mean age was 49.9 years. The mean length of follow-up was 12.9 months. The numbers of relatives affected by pancreatic cancer were 5 in 2 patients (5%), 4 in 5 patients (12.5%), 3 in 17 patients (42.5%), 2 in 14 patients (35%), and 1 in 2 patients (5%). In 4 patients (10%), a p16 mutation was found; in 3, a BRCA2 mutation (7.5%); and in 1, a BRCA1 mutation (2.5%). In 16 patients (40%), MRI revealed a pancreatic lesion: intraductal papillary mucinous neoplasia (14 patients, 35%) and pancreatic ductal adenocarcinoma (2 patients, 5%). One patient had a synchronous intraductal papillary mucinous neoplasia and pancreatic ductal adenocarcinoma. Five patients (12.5%) required surgery (3 for pancreatic ductal adenocarcinoma and 2 for intraductal papillary mucinous neoplasia), while the remaining 35 are under continued surveillance.

Conclusions And Relevance: During a median follow-up of approximately 1 year, pancreatic lesions were detected in 40% of the patients, of whom 5 underwent surgery. Although the study time was relatively short, the surveillance program in individuals at risk seems to be effective.

Citing Articles

New-onset diabetes is a predictive risk factor for pancreatic lesions in high-risk individuals: An observational cohort study.

Baydogan S, Mohindroo C, Hasanov M, Montiel M, Quesada P, Cazacu I Endosc Ultrasound. 2024; 13(2):83-88.

PMID: 38947744 PMC: 11213578. DOI: 10.1097/eus.0000000000000057.


Aspects and outcomes of surveillance for individuals at high-risk of pancreatic cancer.

Bogdanski A, van Hooft J, Boekestijn B, Bonsing B, Wasser M, Klatte D Fam Cancer. 2024; 23(3):323-339.

PMID: 38619782 PMC: 11255004. DOI: 10.1007/s10689-024-00368-1.


The Italian registry of families at risk for pancreatic cancer (IRFARPC): implementation and evolution of a national program for pancreatic cancer surveillance in high-risk individuals.

Archibugi L, Casciani F, Carrara S, Secchettin E, Falconi M, Capurso G Fam Cancer. 2024; 23(3):373-382.

PMID: 38493228 DOI: 10.1007/s10689-024-00366-3.


Can our experience with surveillance for inherited pancreatic cancer help to identify early pancreatic cancer in the general population?.

Lohr J, Ohlund D, Soreskog E, Andersson E, Vujasinovic M, Zethraeus N Fam Cancer. 2024; 23(3):399-403.

PMID: 38441833 PMC: 11255073. DOI: 10.1007/s10689-024-00363-6.


Cost-Effectiveness Analysis of Screening for Pancreatic Cancer Among High-Risk Populations.

Peters M, Eckel A, Seguin C, Davidi B, Howard D, Knudsen A JCO Oncol Pract. 2023; 20(2):278-290.

PMID: 38086003 PMC: 10911581. DOI: 10.1200/OP.23.00495.